Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)

Phase 2

Completed

Conditions: Brain Cancer

Interventions: Radiation: IMRT
Radiation: IMPT
Behavioral: Cognitive Tests
Behavioral: Questionnaires

First Posted Date: 2013-05-15

Last Posted Date: 2024-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT01854554

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neuropathic Pain in Head and Neck Cancer

Conditions: Head and Neck Cancer

Interventions: Behavioral: Questionnaires
Other: Quantitative Sensory Testing

First Posted Date: 2013-05-03

Last Posted Date: 2022-05-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 838

Registration Number: NCT01846286

Locations: 🇺🇸
Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Testing Accountability in Patient Adherence

Conditions: Head And Neck Cancer

Interventions: Other: Swallowing Exercises
Behavioral: Symptom Inventory
Behavioral: Questionnaires

First Posted Date: 2013-05-01

Last Posted Date: 2019-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 225

Registration Number: NCT01844557

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: Ra-223 Dichloride

First Posted Date: 2013-04-17

Last Posted Date: 2021-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01833520

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: Placebo Nasal Spray
Drug: Fentanyl Pectin Nasal Spray
Other: Walk Test
Behavioral: Questionnaires
Behavioral: Mental Ability Tests

First Posted Date: 2013-04-16

Last Posted Date: 2023-06-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT01832402

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: ABI-007
Drug: Ipilimumab
Behavioral: Phone Call

First Posted Date: 2013-04-09

Last Posted Date: 2022-02-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01827111

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Outcome of Colonoscopy Screening and Surveillance

Conditions: Gastroenterology

Interventions: Other: Chart Review

First Posted Date: 2013-04-09

Last Posted Date: 2019-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5000

Registration Number: NCT01827241

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Erythroid Leukemia
Blasts Under 20 Percent of Bone Marrow Nucleated Cells
Myelodysplastic Syndrome
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Therapy-Related Acute Myeloid Leukemia
Therapy-Related Myelodysplastic Syndrome
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Biological: Aldesleukin
Biological: Allogeneic CD56-positive CD3-negative Natural Killer Cells
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study

First Posted Date: 2013-04-04

Last Posted Date: 2023-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT01823198

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Phase 3

Terminated

Conditions: Infection

Interventions: Drug: Pegylated Interferon Alfa 2a
Drug: Ribavirin
Drug: Telaprevir

First Posted Date: 2013-04-01

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01821963

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Plerixafor for Stem Cell Mobilization in Normal Donors

Phase 2

Completed

Conditions: Blood And Marrow Transplantation

Interventions: Drug: Filgrastim
Drug: Plerixafor
Procedure: Apheresis Procedure

First Posted Date: 2013-03-26

Last Posted Date: 2019-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01818284

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy